Journal articleJ Clin Oncol2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
- Journal
- J Clin Oncol
- Published
- 23 April 2007
- Citations
- 2,741
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 8
- Its registry lists this paper as resultsGemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer NCT00026338↗
- BackgroundUsing Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment NCT06574620↗
- BackgroundProspectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis NCT02869802↗
- BackgroundAcelarin First Line Randomised Pancreatic Study NCT03610100↗
- BackgroundImmune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unre… NCT02311361↗
- BackgroundPerioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer NCT00892242↗
- BackgroundLag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer NCT00732082↗
- BackgroundOSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. NCT00040183↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.